Neoadjuvant chemoimmunotherapy combined with surgery for patients with non-small-cell lung cancer staged as ⅢA
10.3760/cma.j.cn112434-20200214-00039
- VernacularTitle:新辅助抗PD-1免疫治疗联合化疗后手术治疗ⅢA期非小细胞肺癌临床分析
- Author:
Fenghuan SUN
1
;
Jie YANG
;
Tao GE
;
Haoran XIA
;
Jie DAI
;
Xiaogang LIU
;
Jiaqi LI
;
Likun HOU
;
Liang DUAN
;
Chunyan WU
;
Yuming ZHU
;
Gening JIANG
;
Peng ZHANG
Author Information
1. 同济大学附属上海市肺科医院胸外科 200433
- Keywords:
Neoadjuvant therapy;
NSCLC;
Anti-PD-1 immunotherapy;
Surgery
- From:
Chinese Journal of Thoracic and Cardiovascular Surgery
2021;37(9):516-520
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the efficacy and safety of neoadjuvant chemoimmunotherapy combined with surgery for stage ⅢA NSCLC patients.Methods:Six patients with NSCLC who were diagnosed as ⅢA and received two cycles of neoadjuvant chemoimmunotherapy and surgery between September 2019 and January 2020 were described in this study.Results:Five of them experienced AEs during neoadjuvant therapy. All of them received surgery and achieved an MPR of 50%. No viable tumor cells were found in the tissues of one patient. One patient with a small bronchopleural fistula after lobectomy.Conclusion:Neoadjuvant chemoimmunotherapy combined with surgery for stage ⅢA NSCLC patients is safe and efficient. Long-term outcomes of neoadjuvant chemoimmunotherapy combined with surgery should be further validated.
